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Patients with schizophrenia often exhibit impairment in working memory that is 
influenced by dopamine availability in the prefrontal cortex. Dopamine availability in the 
prefrontal cortex is regulated in part by the activity of the Catechol-O-Methyl transferase 
(COMT) gene. The COMT gene contains a functional polymorphism that results in a 
Valine (Val) to Methionine (Met) amino acid substitution that impacts dopamine 
availability. COMT impacts working memory performance in patients with schizophrenia 
such that Val allele load is associated with impaired working memory performance. The 
present study extended this literature by examining the relationship between COMT and 
spatial working memory (SWM), and their interactions, in psychometrically identified 
positive and negative schizotypy in a nonclinically ascertained sample of young adults. 
As hypothesized, negative schizotypy was associated with the Val allele in an allele 
dependent fashion. In addition, negative, but not positive, schizotypy was generally 
associated with deficits in SWM performance. Contrary to hypotheses, poorer SWM was 
not associated with Val allele load. Additionally, COMT generally did not moderate the 
relations between SWM and negative schizotypy. The findings support the idea that the 
neurodevelopmental vulnerability for schizophrenia is expressed across a continuum of 
impairment referred to as schizotypy, the construct validity of a multidimensional model 
of schizotypy, and the use of psychometric screening inventories as promising tools to 
help understand the etiology and development of schizophrenia. 
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CHAPTER I 
INTRODUCTION 
 
 
Patients with schizophrenia and non-clinical schizotypes often exhibit impairment 
in working memory, which is presumed to be influenced by prefrontal dopamine 
availability largely controlled by Catechol-O-Methyl transferase (COMT). Current 
neurodevelopmental models posit that the vulnerability for schizophrenia is expressed 
across a dynamic continuum of clinical and subclinical impairment referred to as 
schizotypy. The present study examined the relations and interactions between COMT, 
spatial working memory (SWM), and psychometrically identified positive and negative 
schizotypy in a nonclinically ascertained sample of young adults.  
Current etiological models conceptualize schizophrenia as a neurodevelopmental 
disorder
1
 (Fatemi & Folsom, 2009; Rapoport et al., 2005; Andreasen, 1999; Meehl, 1990; 
Weinberger, 1987). The neurodevelopmental hypothesis posits that the liability for 
schizophrenia arises from neural dysmaturation – a subtle disruption in brain 
development that begins in the prenatal period with full blown clinical expression usual 
occurring in late adolescence or early adulthood (Andreasen, 1999). Neural 
dysmaturation does not necessarily lead to schizophrenia, but rather is expressed across a 
                                                          
1
 The etiology of schizotypy and spectrum disorders involves a process of disrupted neural development. 
However, it has been suggested that negative symptom schizophrenia, as well as the consequences of the 
disorder, may result in neurodegeneration in patients with an unremitting course of illness (Jarskog, 
Gilmore, & Lieberman, 2004).  
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continuum of impairment referred to as schizotypy (Meehl, 1990). This formulation 
suggests that schizophrenia and schizophrenia-spectrum disorders can be best 
conceptualized as the most severe manifestations of illness along the schizotypy 
continuum. Thus, neural dysmaturation appears to be necessary, but not sufficient, for the 
development of full-blown schizophrenia, and is expressed across the schizotypy 
continuum. 
The process of neural dysmaturation is presumed to result from the interaction of 
multiple risk factors including genetic inheritance, gene expression, pre- and peri-natal 
insults, and other biopsychosocial stressors. Although neural dysmaturation occurs across 
development, there are several critical periods in which disruptions in neural 
development markedly heighten the risk for schizotypy, and thus schizophrenia (e.g., 
Cannon et al., 2003). These include disruptions in crest cell migration during the second 
trimester in utero, perinatal complications, and disruptions in the timing and nature of 
synaptic pruning.  
A major consequence of neural dysmaturation is the finding of neuroanatomical 
abnormalities in the prefrontal cortex (e.g., Andreasen et al., 1996), and the functional 
deficits reported both in functional magnetic resonance imaging and neuropsychological 
studies in patients with schizophrenia (e.g., Egan et al., 2001). Evidence points to 
dysfunction in multiple brain regions connected to the prefrontal cortex, including the 
cerebellum, striatum, thalamus, temporal cortex, and parietal cortex (Weinberger et al., 
2001), suggesting that neural dysmaturation can best be understood as an expression of 
mal-distributed brain circuitry that leaves an individual vulnerable for schizophrenia.  
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Schizotypy 
Schizotypy represents the expression of the neurodevelopmental vulnerability for 
schizophrenia (Meehl, 1990). Although the majority of people with this vulnerability will 
never decompensate into clinical schizophrenia
2
, they often exhibit mild or transient 
features of the disorder including cognitive, emotional, and biobehavioral symptoms. 
Thus, schizotypy is expressed along a dynamic continuum ranging from relative 
psychological health to subclinical deviance to schizophrenia-spectrum personality 
disorders to full-blown schizophrenia. Schizotypy is multidimensional in nature, with 
positive and negative schizotypy being the most consistently replicated factors (Claridge 
et al., 1996; Kwapil, Barrantes-Vidal, & Silvia, 2008; Vollema & van den Bosch, 1995). 
Positive schizotypy reflects an excess or distortion of normal functions that includes 
magical thinking and delusions, as well as perceptual illusions and hallucinations. 
Negative schizotypy refers to a diminution or loss of normal functions such as social 
anhedonia, affective flattening, alogia, and avolition. The severity of these features can 
range from subclinical deviance to the debilitating symptoms seen in full-blown 
schizophrenia.  
There is considerable evidence that supports the schizotypy continuum as an 
expression of neurodevelopmental vulnerability for schizophrenia. Patients with 
schizophrenia often exhibit mild and transient signs of the disorder long before they 
decompensate (e.g., Chapman, Chapman, Kwapil, Eckblad, & Zinser, 1994; Walker, 
                                                          
2
 Meehl (1990) suggested that about 10% of the population is schizotypic and that about 10% of 
schizotypes will decompensate into schizophrenia (neatly arriving at the 1% lifetime prevalence rate for 
schizophrenia). Meehl’s conjectures were not empirically derived; however, subsequent taxometric 
analyses have supported his estimates (e.g., Horan, Blanchard, Gangestad, & Kwapil, 2004; Lenzenweger 
& Korfine, 1992). 
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Savoie, & Davis, 1994). Compensated relatives of patients with schizophrenia (who are 
presumed to share genetic liability) often exhibit signs of schizotypy (e.g., Cannon et al., 
1994; Erlenmeyer-Kimling et al., 1993). Likewise, putative schizotypes identified by 
clinical status or psychometric inventories exhibit similar patterns of cognitive and 
biobehavioral deficits (e.g., impairment in sustained attention, dermatoglyphic anomalies, 
and neurological soft signs) as patients with schizophrenia (e.g., Bergida & Lenzenweger, 
2006; Chok, Kwapil, & Scheuermann, 2005; Kaczorowski, Barrantes-Vidal, & Kwapil, 
2009), albeit to a lesser degree.  
Taken together, the evidence suggests that the schizotypy continuum is a 
promising construct from which to study the neurodevelopment of schizophrenia. In 
addition, the identification and study of nondisordered schizotypes: 1) avoids confounds 
associated with the catastrophic sequelae of schizophrenia itself (such as hospitalization, 
medication, and social stigma); 2) should enhance our understanding of the etiology and 
development of schizophrenia- spectrum disorders, including the identification of risk 
and protective factors; and 3) is essential for the development and implementation of 
prophylactic treatment interventions.  
Psychometric identification of schizotypy has reliably predicted the development 
of schizophrenia symptoms and spectrum disorders at follow-up assessments. For 
example, Chapman et al. (1994) re-interviewed 95% of 534 putatively schizotypic and 
control participants at a ten-year follow-up assessment. They found that participants 
initially identified by the Magical Ideation (Eckblad & Chapman, 1983) and Perceptual 
Aberration (Chapman, Chapman, & Raulin, 1978) Scales had higher rates of psychosis 
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compared to control participants at the follow-up assessment. Moreover, participants who 
were identified by the scales at the initial assessment, but did not develop psychosis, still 
displayed more schizotypal, paranoid, and psychotic-like symptoms compared to the 
control group at the follow-up assessment. Likewise, Kwapil (1998) found that 24% of 
participants identified by the Revised Social Anhedonia Scale (Eckblad, Chapman, 
Chapman, & Mishlove, 1982) compared to 1% of the control participants exhibited 
schizophrenia-spectrum illnesses at the ten-year follow up assessment. 
Schizophrenia, Schizotypy, and Working Memory 
The process of neural dysmaturation results in abnormalities in the prefrontal 
cortex. Animal and human studies suggest that working memory processes are controlled 
by the neural circuitry of the prefrontal cortex, particularly the dorsolateral prefrontal 
cortex (e.g., Goldman-Rakic, 1994; Goldman-Rakic, Muly, & Williams, 2000; Goldman-
Rakic & Selemon, 1997). Baddeley (1986) conceptualized working memory as a system 
involving both processing and storage components that maintain access to mental 
representations. Engle and Kane (2004) argued that attentional control processes are at 
the core of working memory capacity. Like Engle and Kane (2004), Park and colleagues 
emphasize maintaining mental representations active above threshold and under the focus 
of attention, especially during distractions, as a key component of working memory (e.g., 
Lee & Park, 2005). This definition of working memory will be adopted throughout this 
proposal.  
Park and Holzman (1992) were the first to document working memory deficits in 
patients with schizophrenia. Following this, numerous studies and meta-analyses (e.g., 
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Forbes, Carrick, McIntosh, & Lawrie, 2009; Lee & Park, 2005) reported working 
memory deficits in patients with schizophrenia. In a meta-analysis of 124 studies, Lee 
and Park (2005) reported that: 1) working memory deficits occur in schizophrenia; 2) 
working memory deficits are not domain specific; however, patients show more 
consistent impairments in visual-spatial working memory compared to verbal working 
memory tasks; and 3) increasing delay time does not increase working memory deficits 
beyond those seen after one second. Forbes et al. (2009) built upon this meta-analysis and 
demonstrated that working memory deficits are not due to differences in intellectual 
ability between patients with schizophrenia and healthy control participants. Moreover, 
several researchers define working memory deficits as a core feature of schizophrenia 
(Gold, Carpenter, Randolph, Goldberg, & Weinberger, 1997; Goldman-Rakic, 1994).  
Numerous tasks are used to assess working memory in patients with 
schizophrenia including the N-back Task (e.g., Gevins et al., 1996), Oculomotor Delayed 
Response Task, working memory subscales from the Wechsler Adult Intelligence Scale 
(e.g., Wechsler, 1997), the failure to maintain set index from the Wisconsin Card Sorting 
Task (e.g., Harris, 1988), and the SWM task (Owen, Downes, Sahakian, Polkey, & 
Robbins, 1990) from the Cambridge Neuropsychological Test Battery (CANTAB). 
Although all of these tasks are useful for examining working memory processes, the 
SWM task from the CANTAB has several notable strengths. First, the CANTAB battery 
can be used in both humans and rodents (Geyer, 2008). Secondly, neuroanatomical and 
neurofunctional studies of the SWM task indicate that it draws upon resources from the 
dorsolateral prefrontal cortex (e.g., Owen, Doyon, Petrides, & Evans, 1996; Owen, 
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Evans, & Petrides, 1996) and correlates with antisaccade errors (e.g., Hutton et al., 2004). 
Therefore, this proposal and literature review will focus on the CANTAB SWM task. 
A large literature demonstrates that patients with schizophrenia make significantly 
more errors than healthy control participants on the CANTAB SWM task (Badcock, 
Michiel, & Rock, 2005; Cocchi et al., 2009; Hutton et al., 2004; Hutton et al., 1998; 
Joyce et al., 2002; Joyce, Hutton, Mutsatsa, & Barnes, 2005; Pantelis et al., 1997; 
Pantelis et al., 2009; Tyson, Laws, Roberts, & Mortimer, 2005). Several studies indicated 
that the magnitude of the difference in errors between patients and healthy control 
participants increases as difficulty level rises (e.g., Hutton et al., 1998; Joyce et al., 2002; 
Pantelis et al, 1997). In addition, patients with schizophrenia perform significantly worse 
on this task than patients with bipolar disorder (Badcock et al., 2005), Parkinson’s 
disease, frontal lobe lesions, and temporal lobe/amygdalo-hippocampal lesions (Pantelis 
et al., 1997), but not patients with Alzheimer’s disease (Gabrovska-Johnson et al., 2003). 
Performance on the SWM task does not appear to be impacted by medication (e.g., 
Barrett, Bell, Watson, & King, 2004), substance use (e.g., Barnes, Mutsatsa, Hutton, 
Watt, & Joyce, 2006; McCartan et al., 2001), or change across a 9-month interval (Tyson 
et al., 2005). 
 Although patients with schizophrenia consistently show impairment on the 
CANTAB SWM task, the majority of studies failed to examine the relation of positive 
and negative symptoms with performance on this task. However, several studies reported 
a relation between negative symptoms (Pantelis et al., 2004; Pantelis, Stuart, Nelson, 
Robbins, & Barnes, 2001; Pantelis et al., 2009; Wood et al., 2003), one study found a 
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weak association with positive symptoms (Elliot, McKenna, Robbins, & Sahakian, 1998), 
and others found null results (Cocchi et al., 2009; Joyce et al., 2002; Tyson et al., 2005). 
Several researchers (Weinberger, 1987; Weinberger et al., 2001) suggest that negative 
symptoms reflect prefrontal neuronal impairment. For example, Callicott et al. (2000) 
found that decreased N-acetyl aspartate concentration in the dorsolateral prefrontal cortex 
(lower levels indicate neuronal pathology) was related to increased negative, but not 
positive, symptoms and explained 25% of the variance in negative symptoms in patients. 
 Consistent with a continuum model of schizotypy, unaffected, biological relatives 
of patients with schizophrenia tend to demonstrate working memory deficits compared to 
healthy control participants (Conklin, Curtis, Katsanis, & Iacono, 2000; Diwadkar, 
Montrose, Dworakowski, Sweeney, & Keshavan, 2006; Egan et al., 2001; Johnson et al., 
2003; Myles-Worsley & Park, 2002; Park, Holzman, & Goldman-Rakic, 1995). 
O’Conner et al. (2009) are the only group to have used the CANTAB SWM task to 
examine this relationship between genetically high-risk individuals and healthy control 
participants. Although they found no differences between the groups on this task, the 
results are uninterpretable since the groups differed on IQ and the authors inappropriately 
used this variable as a covariate in the analyses.  
Working memory deficits are also reported in schizotypic individuals identified 
by clinical status (i.e., in the prodromal phase or schizophrenia or diagnosed with 
schizotypal personality disorder).  For example, Wood et al. (2003) reported that two 
“ultra high-risk” groups from the Edinburgh High Risk Study, one that developed 
psychosis and one that did not, performed significantly worse on the CANTAB SWM 
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task compared to healthy control participants. Moreover, the ultra high-risk psychotic 
group generally performed worse than the non-psychotic risk group on all cognitive 
tasks, although these finding did not reach significance. In addition, only the ultra high 
risk-psychotic group demonstrated a significant relationship between performance on the 
CANTAB SWM task and negative symptoms. Bartok et al. (2005) reported that pre-
psychotic patients scored significantly lower on the CANTAB SWM task compared to 
healthy control participants; however, they did not assess the relation of positive and 
negative symptoms with working memory.  
A growing literature has examined the relation between working memory 
performance and psychometrically identified schizotypy; however, to date, no published 
study has utilized the CANTAB SWM task. Park, Holzman, and Lenzenweger (1995) 
reported that individuals who scored at least 2 standard deviations above the mean on the 
Perceptual Aberration scale (presumed to tap positive schizotypy) performed 
significantly worse on an oculomotor delayed response task compared to individuals who 
scored no higher than .5 standard deviations above the mean on that scale. However, 
when using the Schizotypal Personality Questionnaire (Raine, 1991), Park and McTigue 
(1997) reported a trend for the association of poorer performance on the delayed response 
task with the negative symptom factor and a significant association with the “no close 
friends,” a subscale of the negative symptom factor.  
 Tallent and Gooding (1999) attempted to replicate and extend the findings by 
Park et al. (1995) by including an additional measure of positive schizotypy, the Magical 
Ideation scale, and a measure of negative schizotypy, the Revised Social Anhedonia 
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Scale . They reported that the social anhedonia group (those who scored 2 standard 
deviations above the mean on the scale) and the perceptual aberration/magical ideation 
group (those who score 2 standard deviations on at least one of the scales) performed 
significantly worse than healthy control participants, but did not differ from each other on 
working memory performance as assessed by a delayed response working memory task. 
However, the social anhedonia group had slower reaction times than either group. 
Importantly, the social anhedonia score accounted for significant variance in working 
memory task accuracy over and above the perceptual aberration/magical ideation score. 
Using structural equation modeling, Smyrnis et al. (2007) reported that only 
negative and paranoid schizotypy (with loadings from the Schizotypal Personality 
Disorder Questionnaire) were related to cognitive performance accuracy based upon 
verbal and spatial versions of the N-back task (Gevins et al., 1996), Ravens Progressive 
Matrices total score (Raven, 1982), and Continuous Performance Task – Identical Pairs 
version d-prime index (Cornblatt, Lenzenweger, & Erlenmeyer-Kimling, 1989; Cornblatt, 
Risch, Faris, Friedman, & Erlenmeyer-Kimling, 1988). Specifically, higher negative 
schizotypy scores were related to poorer cognitive performance whereas higher paranoid 
schizotypy scores were related to better cognitive performance. However, it is difficult to 
draw conclusions from this study regarding working memory because the composite also 
included non-working memory tasks. Moreover, the structural equation model is largely 
uninterpretable due to the use of unstandardized coefficients and concerns related to the 
authors’ post hoc decision to drop latent factors from the model.   
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Kerns and Becker (2008) reported that a disorganized schizotypy group, that 
included individuals who score 1.96 standard deviations above the mean on the Cognitive 
Slippage scale (Miers & Raulin, 1987), performed more poorly than control participants 
(individuals who scored no higher than .5 standard deviations above the mean on the 
scale) on a 3-back working memory task. In contrast, using a backward elimination 
regression approach, Matheson and Langdon (2008) reported that lower scores on letter-
number sequencing were related to higher scores on the cognitive/perceptual and 
interpersonal factors of the Schizotypal Personality Disorder Questionnaire. However, it 
is difficult to interpret these results given that the statistical approach was not based on a 
priori hypotheses. Finally, a few studies reported no relation between working memory 
performance and psychometrically identified schizotypy (Lenzenweger & Gold, 2000; 
Noguchi, Hori, & Kunugi, 2008).  
Catechol-O-Methyl transferase 
The COMT gene is located on chromosome 22 at band q11.2. COMT promoters 
(P1 and P2) control transcription of two different messenger ribonucleic acids (Chen et 
al., 2004; Tenhunen, Salminen, Jalanko, Ukkonen, & Ulmanen, 1993). P1 encodes 
soluble COMT and P2 encodes membrane bound COMT. Soluble COMT is expressed in 
the liver, blood, and kidneys, whereas membrane bound COMT is expressed 
predominately in prefrontal regions of the brain. They differ in substrate affinities and 
capacities, with membrane bound COMT having a 10-fold greater affinity (despite a 
smaller capacity) for catecholamines such as dopamine (Lotta et al., 1995; Tunbridge, 
Harrison, & Weinberger, 2006); therefore, membrane bound COMT is involved in 
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metabolizing dopamine found in prefrontal regions of the brain. Henceforth, this 
document will refer to the COMT Val158Met polymorphism when discussing COMT. 
COMT contains a functional polymorphism, a G → A substitution at exon 4, 
which results in a Valine (Val) to Methionine (Met) amino acid substitution at codon 158 
in membrane bound-COMT (Lachman et al., 1996). The enzyme activity of Val (the high 
activity allele) is ~40% higher than that of Met (the low activity allele) at 37 degrees 
Celsius in postmortem human dorsolateral prefrontal cortex (Chen et al., 2004). Thus, 
Val homozygotes (i.e., those with two copies of the same allele) have increased COMT 
activity in their prefrontal cortex compared to Met homozygotes, with Val/Met 
heterozygotes (i.e., those with one copy of each allele) falling in the middle because 
alleles are codominant (Chen et al., 2004; Tunbridge et al., 2006).  
Although synaptic dopamine transporters have a much higher affinity towards 
dopamine than COMT, they are found in low quantities in the prefrontal cortex and do 
not impact extracellular dopamine levels (Chen et al., 2004; Lewis et al., 2001; 
Weinberger et al., 2001). Therefore, COMT is largely responsible for dopamine 
metabolism in the prefrontal cortex (Chen et al., 2004; Weinberger et al., 2001). This 
presumably results in Val homozygotes having less available dopamine in prefrontal 
regions of the brain compared to Met homozygotes, with heterozygotes falling in the 
middle (Chen et al., 2004). The notion that COMT is critical for metabolizing dopamine 
in the prefrontal cortex is supported by animal studies. For example, Tunbridge et al. 
(2004) found that a COMT inhibitor, tolcapone, doubled dopamine, but not noradrenaline 
levels, in the rat prefrontal cortex when catecholamine efflux was induced. In addition, 
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Gogos et al. (1998) reported that male COMT knockout mice showed a two- to three-fold 
increase in frontal dopamine levels, but no dopamine changes in other regions.  
Since COMT is expressed in prefrontal regions of the brain, and COMT genotype 
differentially influences COMT enzymatic activity and thus prefrontal dopamine 
availability, one would expect COMT genotype to differentially impact prefrontally 
mediated cognitive processes such as working memory. Although the literature is 
inconsistent regarding this association (e.g., Egan et al. 2001; Barnett et al., 2007, Barnett 
et al., 2008; Liao et al., 2009; Wishart et al., 2011), there is considerable theoretical and 
empirical evidence that suggests that COMT plays a small but significant role in 
moderating working memory processes. Study characteristics such as task and sample 
variability and sample size likely contribute to the inconsistent findings in the literature. 
Note that COMT is just one source of variation that contributes to working memory 
performance and it would be naïve to assume that the differences in complex phenotypes 
such as working memory can be perfectly mapped to COMT. 
Schizophrenia, schizotypy, and COMT. Linkage studies have identified COMT 
as a susceptibility gene for schizophrenia (e.g., McGuffin, Tandon, & Corsico, 2003; 
Owen, Williams, & O'Donovan, 2004). However, the results from individual studies are 
largely inconclusive (Daniels et al., 1996; Fan et al., 2005; Glatt, Faraone, & Tsuang, 
2003; Kremer et al., 2003; Okochi et al., 2009; Sazci et al., 2004; Shifman et al., 2002). A 
few studies (Egan et al., 2001; Kunugi et al., 1997) and meta-analyses (e.g., Glatt et al., 
2003) suggest that the Val allele represents a small, but reliable risk factor for 
schizophrenia. In addition, Shifman et al. (2002) found the Val allele to be associated 
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with schizophrenia in a large sample of Ashkenazi Jews. This relationship was even 
stronger when examining a COMT haplotype, which included the Val allele.  
Few studies have assessed whether COMT is related to the clinical presentation of 
patients with schizophrenia. Strous et al. (2006) found no relationship between COMT 
genotype and clinical symptoms in patients with schizophrenia, whereas another found an 
association between the Val allele and negative symptoms (i.e., Wang et al., 2010) and 
others reported and relation with positive symptoms (Goghari & Sponheim, 2008; 
Molero, Ortuno, Zalacain, & Patino-Garcia, 2007). Furthermore, Han et al. (2006) 
reported that individuals with schizophrenia who were homozygous for the Val allele 
displayed more inappropriate affect than those homozygous for the Met allele. However, 
the Met allele has also been associated with aggressive (Han et al., 2006; Lachman, 
Nolan, Mohr, Saito, & Volavka, 1998; Strous et al., 2003) and suicidal behavior (Nolan 
et al., 2000) in patients with schizophrenia.  
Consistent with the continuum model of schizotypy, several studies have 
examined the impact of COMT in individuals identified as part of the schizotypy 
continuum by consanguinity or psychometric screening inventories. Docherty and 
Sponheim (2008) found that relatives of patients with schizophrenia who were 
homozygous for the Val allele had the highest scores on the Social Anhedonia and 
Physical Anhedonia Scales (Chapman, Chapman, & Raulin, 1976) compared to healthy 
controls; however, COMT was unrelated to scores on the Magical Ideation or Perceptual 
Aberration Scales. In addition, there was no relation between COMT and relatives of 
patients with bipolar disorder or healthy controls. However, Schurhoff et al. (2007) found 
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that scores on the positive and negative dimension of the Schizotypal Personality 
Questionnaire in relatives of patients with schizophrenia were both related to Val 
homozygosity, but not Val/Met heterozygosity or Met homozygosity. Moreover, there 
was a stepwise relation such that Val homozygotes had the highest scores on these 
dimensions and Met homozygotes had the lowest scores, with heterozygotes falling in the 
middle.  
 Stefanis and colleagues (Avramopoulos et al., 2002; Smyrnis et al., 2007; Stefanis 
et al., 2004) used a sample of male Greek conscripts to examine the relation of COMT 
with scores on the Schizotypal Personality Questionnaire. Avramopoulos et al. (2002) 
reported that higher total scores were related to COMT in a step-wise fashion with Val 
homozygotes scoring the highest, Met homozygotes scoring the lowest, and Val/Met 
heterozygotes falling in the middle. These researchers also administered the Perceptual 
Aberration Scale and found a slightly different order – Val homozygotes had the highest 
scores, followed by Met homozygotes, and then Val/Met heterozygotes. Building upon 
Avramopolous et al. (2002), Stefanis et al. (2004) reported that Val allele load was 
increasingly associated with the negative and disorganized dimensions of the Schizotypal 
Personality Questionnaire. Finally, Smyrnis et al. (2007) found that Val homozygosity 
was significantly related to higher scores on the negative and disorganized factors, 
whereas Val/Met heterozygosity and Met homozygosity was significantly related to the 
paranoid factor. In addition, Val homozygotes had significantly higher scores on many of 
the Symptom Check List–90 (Derogatis, 1993) subscales compared to Val/Met 
heterozygotes or Met homozygotes. Due to the concerns noted previously, however, these 
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results should be interpreted cautiously. In contrast to these results, Sheldrick et al. 
(2008) found that Met homozygosity was associated with increasing scores on the 
disorganized dimension of the Schizotypal Personality Questionnaire – Brief Version. 
 A few studies failed to find associations between COMT and schizotypy. For 
example, Ettinger et al. (2006) found no relation using the Rust Inventory of Schizotypal 
Cognitions (Rust, 1989). However, the validity of the Rust Inventory as a measure of 
schizotypy has not been well established (Chapman, Chapman, & Kwapil, 1995). In 
addition, Ma et al. (2007) did not find a relation between COMT and the Schizotypal 
Personality Questionnaire in a large sample of healthy Chinese participants after 
correction for multiple comparisons. The authors noted that population stratification 
effects may have impacted their results.  
COMT and Working Memory in Schizophrenia and Schizotypy 
Several studies (e.g., Egan et al., 2001; Goldberg et al., 2003; Barnett et al., 2007; 
Wishart et al., 2011; Wirgenes et al., 2010; Bilder et al., 2002; Gallinat et al., 2003), but 
not all (e.g., Barnett et al., 2008), have shown that performance on working memory tasks 
and other tasks presumed to draw upon prefrontal resources is systematically related to 
COMT genotype in adults. In a seminal study, Egan et al. (2001) examined the relation 
between COMT and working memory performance. Patients with schizophrenia and their 
unaffected biological siblings underwent functional magnetic resonance imaging while 
performing an N-back task. Patients and siblings were matched for task performance. 
Genotype groups within the patients and siblings did not differ on performance accuracy; 
however, Met load predicted prefrontal physiological efficiency such that Met 
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homozygotes were more efficient than Val homozygotes with heterozygotes falling in the 
middle, when matched for overall accuracy. This pattern of efficiency was similar in both 
the sibling and patient groups; however the authors did not indicate whether the level of 
efficiency was statistically different between the groups. These data suggest that the 
impact of COMT on working memory processes is not specific to schizophrenia, but 
rather a generalizable human characteristic (Egan et al., 2001; Weinberger et al., 2001).  
Mattay et al. (2003) demonstrated how increasing dopamine levels either had a 
favorable or unfavorable impact on working memory performance based on COMT 
genotype. Specifically, they examined the effect of COMT on prefrontal efficiency (as 
assayed by functional magnetic resonance imaging) during the N-back Test both on and 
off amphetamines (which are presumed to increase dopamine neurotransmission). Mattay 
et al. found that, compared to the placebo condition, the amphetamine condition resulted 
in Val homozygotes showing enhanced prefrontal efficiency and decreased reaction time 
at all levels of task difficulty on the N-back Test; however, it did not influence 
performance accuracy. In contrast, the amphetamine condition had no effect on the 
prefrontal efficiency of Met homozygotes in low to moderate difficultly conditions, but 
caused less efficient processing, a decrease in performance, and an increase in reaction 
time at high difficultly conditions. Val/Met heterozygotes showed consistent performance 
across task difficulty, but improved prefrontal efficiency in the amphetamine condition. 
These data support the idea that prefrontal dopamine levels, which are regulated by 
COMT genotype, impact working memory performance and that there is an “optimal 
range” of dopamine availability.  
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Surprisingly, Smyrnis et al. (2007) is the only study to examine the relation 
between COMT, working memory, and schizotypy. They found that increasing Val load 
was associated with a “dose dependent increase” in the factor loading between negative 
schizotypy and the cognitive performance accuracy composite, such that higher scores on 
the negative schizotypy factor were associated with lower cognitive performance 
accuracy. As mentioned previously, however, the results are largely uninterpretable due 
to the inclusion of non-working memory tasks in the composite, the use of 
unstandardized coefficients in the structural equation model, and concerns related to the 
exclusion of additional latent factors.  
Goals and Hypotheses of the Present Study  
The present study sought to extend the current literature by examining the 
relations of COMT and working memory with psychometrically identified positive and 
negative schizotypy in a nonclinically ascertained sample of young adults. Only one 
study (Smyrnis et al., 2007) has examined the relation between COMT and cognitive 
performance in psychometrically identified schizotypy and the results are largely 
uninterpretable. The following hypotheses were offered: 
1. Higher scores on negative schizotypy would be related to increasing Val load; 
however, no hypothesis was offered with positive schizotypy due to inconsistent 
findings in the literature. 
2. Negative, but not positive schizotypy, would be associated with poorer 
performance on the SWM task. 
3. Poorer performance on SWM would be associated with Val allele load. 
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4. COMT would moderate the relation between working memory and negative 
schizotypy, with Val allele load being associated with more impaired performance 
on this task. 
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CHAPTER II 
METHOD 
 
 
Participants 
The sample was drawn from an archival dataset of 407 college undergraduates 
who were enrolled in general psychology courses at the University of North Carolina at 
Greensboro (UNCG) from January 2007 to May 2008. From this initial sample, a total of 
29 participants had unusable schizotypy data due to their scores on an infrequency scale 
(Chapman & Chapman, 1983), 58 participants did not have COMT genotyping data, and 
1 participant did not have SWM data. In addition, 8 participants were excluded due to 
being statistical outliers on the schizotypy measures. In order to maximize power, 
different samples were used from the original sample of 407 participants. This resulted in 
a sample of 312 participants to examine the relation between COMT and positive and 
negative schizotypy, 369 participants to assess the relation between positive and negative 
schizotypy and SWM, and 311 participants to examine the impact of COMT on SWM in 
positive and negative schizotypy.
3
 Demographic data is reported for the largest sample (n 
                                                          
3
 All three samples came from the overall sample of 407 participants. A total of 312 participants were used 
to examine the relation between COMT and schizotypy (29 participants were dropped due to unusable 
schizotypy data, 58 did not have COMT data, 8 participants were outliers). A total of 369 participants were 
used to examine the relation between COMT and SWM (29 participants were dropped due to unusable 
schizotypy data, 1 participant had no SWM data, and 8 participants were outliers). A total of 311 
participants were used to examine the impact of COMT on SWM in positive and negative schizotypy (29 
participants were dropped due to unusable schizotypy data, 58 did not have COMT data, 1 had no SWM 
data, and 8 participants were outliers). 
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= 369); however, there were no significant differences in terms of demographic variables 
between the largest sample and the other samples. 
The mean age of the sample at the time of the assessment was 19.4 (SD = 2.88, 
range = 17 – 41) years. The sample consisted of 49 Caucasian males, 186 Caucasian 
females, 11 African-American males, 83 American-American females, 3 Asian males, 7 
Asian females, 12 Hispanic females, 6 males and 11 females who were classified as other 
(i.e., not Caucasian, African-American or Asian, or Hispanic), and 1 female who did not 
specify her race. This composition is consistent with the university demographics.  
Materials 
Schizotypy Questionnaires 
The schizotypy questionnaires included the Perceptual Aberration, Magical 
Ideation, Physical Anhedonia, and Revised Social Anhedonia Scales, and an infrequency 
scale. The Perceptual Aberration Scale contains 35 items that tap psychotic-like 
perceptual experiences and bodily distortions. The Magical Ideation Scale consists of 30 
items that assess belief in improbable or invalid causality. The Revised Social Anhedonia 
Scale includes 40 items that tap asociality and indifference towards interpersonal 
relationships. The Physical Anhedonia Scale is comprised of 61 items that assess deficits 
in sensory and aesthetic pleasure. The Perceptual Aberration and Magical Ideation Scales 
assess positive schizotypy, and the Physical Anhedonia Scale taps negative schizotypy. 
The Revised Social Anhedonia Scale appears to assess both positive and negative 
schizotypy. Exploratory and confirmatory factor analyses of the four scales reliably 
produce two factors, labeled positive and negative schizotypy, that account for 
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approximately 80% of the variance in the measures (Brown, Silvia, Myin-Germeys, 
Lewandowski, & Kwapil, 2008; Kwapil et al., 2008; Lewandowski et al., 2006). 
Participants were assigned positive and negative schizotypy dimensional scores, based 
upon factor loadings derived from a sample of 6,137 college students (Kwapil et al., 
2008). The infrequency scale consists of 13 items and is designed to screen out 
participants who respond in a random or “fake-bad” manner. Participants who endorsed 
more than two of these items were omitted from further study. The schizotypy 
questionnaires are widely used and have good internal consistency (.82-.92). See 
Appendix A for a copy of the schizotypy questionnaires.   
Cambridge Neuropsychological Test Battery (CANTAB) Spatial Working Memory 
(SWM) 
The CANTAB (Owen et al., 1990) battery includes a total of 22 computerized 
tasks designed to measure various cognitive processes. It has been used extensively to 
examine various cognitive processes in patients with schizophrenia. The SWM task from 
the CANTAB was used in the present study. The SWM task measures a participant’s 
ability to retain and manipulate spatial information in memory. The goal of the task is for 
participants to search a set of boxes presented on the computer screen for a series of blue 
tokens. The participant determines the search order. Participants are instructed that boxes 
that already contained a blue token will never contain another blue token; therefore, they 
should not touch those boxes again. The task takes approximately eight minutes to 
complete. 
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The SWM task begins with a sample trial in which the examiner explains the task 
to the participant. The sample trial consists of three boxes to search through. Next, the 
participant is administered a practice set consisting of three trials with three boxes each. 
Note that a set consists of a predetermined number of trials and a trial consists of the 
searches needed to fill the column on the right side of the computer screen with the blue 
tokens. The boxes remain in the same position between trials and change positions 
between sets. In other words, the participant sees the same display of boxes on the 
computer screen for each set; however, the display of boxes on the computer screen 
changes between sets.  If the participant chooses a box that has already contained a blue 
token during the practice trials, the examiner reminds the participant that the computer 
will never hide the blue token in that box again. The test consists of three sets: four trials 
with four blocks each, four trials with six blocks each, and four trials with eight blocks 
each. Note that the color of the boxes changes between trials. 
The SWM task contains several outcome measures. SWM between errors occur 
when a participant chooses a box that already contained a blue token between test trials. 
SWM within errors occur when a participant returns to a box that did not contain a blue 
token within a trial. SWM double errors are defined as errors that could be considered 
either between or within errors. The SWM task also yields a total error count for each of 
the domains (between, within, and double). In addition, the SWM task yields several 
latency measures including: 1) mean time to first response for trials with 4, 6, and 8 
boxes; 2) mean time to last response for trials with 4, 6, and 8 boxes; and 3) mean token 
search-preparation time for trials with 4, 6, and 8 boxes. Owen et al. (1990) indicated that 
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starting with a specific box and returning to that box once a blue token has been 
identified is an efficient strategy to employ between sets within a trial. Lower scores 
reflect superior strategy. 
Genotyping 
All participants were genotyped for COMT Val158Met. Two DNA buccal swabs 
(Isohelix swabs; Boca Scientific) were used to collect DNA by rubbing the inside of each 
participant's cheeks with a swab for 30 seconds prior to placing it in a collection tube 
provided with the Isohelix kit. Nuclear DNA was extracted from the buccal swabs 
following the Isohelix procedures, at the Molecular Biology Core Laboratory at UNCG. 
A random set of samples was subjected to manual SNP genotyping using an Amersham 
sequencing unit and manufacturer's protocols. Spectrophotometer readings (A260/280) 
were taken of all the samples to ensure the relative purity of the DNA. The extracted 
DNA samples were then stored at -20 degrees C and sent as a batch to GeneSeek Inc 
(Lincoln, NE), where single nucleotide polymorphism (SNP) genotype, including the one 
responsible for COMT Val158Met (rs4680), were determined for each subject. The 
random sample of SNP genotypes produced in the Core Laboratory were compared with 
those reported in the GeneSeek database to ensure that the genotyping was accurate (in 
terms of chemistry and sample identification). In every case, the genotype determined by 
GeneSeek matched the one obtained with the Amersham method. The distribution of the 
genotypes obtained for COMT Val158Met for the 312 subjects (Met/Met = 71; Val/Met 
= 143; Val/Val = 98) was consistent with Hardy-Weinberg equilibrium (p > .05). 
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Procedures 
 Participants volunteered to take part in the proposed study through a web-based 
sign-up system. Participants completed the assessments, as well as a larger battery of 
tasks, at an individual testing session. Participants were administered the tasks in the 
following order: DNA sampling, CANTAB motor screening, CANTAB SWM task, and 
the schizotypy questionnaires. Participants who had corrected vision or hearing needed to 
have their correction with them to take part in the study. Consent was obtained from each 
participant. 
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CHAPTER III 
RESULTS 
 
 
Statistical analyses were conducted using MPlus version 6.1 (MPlus 6.1, 2010) 
and SPSS version 18 (SPSS, 2009). A series of preliminary analyses were conducted to 
examine the nature of the schizotypy, SWM, and COMT data. 
Descriptive Statistics and Correlations 
Table 1 presents the mean, standard deviation, minimum, maximum, skew, and 
kurtosis for positive schizotypy, negative schizotypy, COMT, and each SWM variable. 
Note that all SWM latency measures (measured in milliseconds) were rescaled by 
dividing each value by 1000. There were no significant differences between the samples 
(n = 369, n = 312, n = 311) in terms of descriptive statistics. Table 2 presents a zero-order 
correlation matrix of all variables. Spearman correlations were used due to the skewed 
nature of the data. 
Schizotypy Data 
Participants were assigned positive and negative schizotypy dimensional scores 
based on a sample of 6,147 college students (Kwapil et al., 2008). Note that the sample 
included a broad range of scores on the schizotypy dimensions. The skew statistic and 
qualitative inspection of each distribution revealed that the distributions for positive and 
negative schizotypy were highly skewed in the positive direction (see Table 1). Using the 
recommendations of Fidell and Tabachnick (2003), positive and negative schizotypy 
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were transformed by taking the log of each variable. All subsequent analyses were 
computed using the transformed values for positive and negative schizotypy. The 
distributions for both positive and negative schizotypy factors were unimodal and 
correlated modestly, r = .22, p<.001. There were no significant differences between the 
samples (n = 369, n = 312, n = 311) in terms of positive and negative schizotypy. 
Relation of Schizotypy and COMT Val158Met 
As hypothesized, ANOVAs revealed a significant association of COMT with 
negative schizotypy, F(2,309)=6.75, p≤.001, but not positive schizotypy, F(2,309)=.07 
(Kaczorowski et al., 2011). Figure 1 presents the COMT group comparisons. Newman-
Keuls comparisons indicated that the Val/Val group significantly exceeded the Val/Met 
and Met/Met groups on negative schizotypy scores, p<.05 and p<.001, respectively. 
Linear contrast coding indicated that Val allele load was related to negative schizotypy in 
an allele-dependent fashion (p<.001) and accounted for 4% of the variance in negative 
schizotypy.  
Relation of Schizotypy and SWM  
In order to examine the relations of positive and negative schizotypy with SWM 
outcomes, a series of regression analyses with SWM measures (between, within, double 
errors, mean time to first response, mean time to last response, mean token search-
preparation time, and strategy) as the dependent variables were conducted. The SWM 
data has a hierarchical structure in which trial type (i.e., 4, 6, or 8 block conditions are 
level 1 data) is nested within participants (level 2 data). Because trial type was included 
in the analyses to see whether the relations changed across block conditions, multi-level 
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modeling was used. Multilevel modeling is a more powerful approach to analyzing 
nested data compared to the more commonly used unilevel regression analyses (Hox, 
2002; Luke, 2004). 
The multilevel analyses examined two types of relations between positive and 
negative schizotypy and SWM. The first set of analyses assessed the direct effects of the 
level 2 predictors (positive schizotypy, negative schizotypy) on the level 1 criterion  
(between errors, within errors, double errors, mean time to first response, mean time to 
last response, and mean token search-preparation time). The second set of analyses 
examined cross-level interactions of the relations of the level 1 predictor (4, 6, and 8 
block conditions) and criterions (SWM performance) with the level 2 variables (positive 
schizotypy, negative schizotypy). The cross-level interaction analyses tested the effect of 
the level 2 predictors on the level 1 slopes (slope of condition by SWM performance). 
Note that the intercept of the slope evaluates the strength of the relations between the 
level 1 predictor and criterion, independent of the level 2 variables. This provides 
validation of the SWM assessment such that failing to find a relation between trial type 
and performance would raise concerns about the validity of the SWM assessment. A lack 
of cross-level interactions does not mean that there was not a relation between positive 
and/or negative schizotypy and SWM performance. Rather, a cross-level interaction 
clarifies the relation to determine if the relation between the level 1 variable changes as a 
function of the level 2 variable; that is, did the slope of SWM performance across trial 
type change across levels of schizotypy. 
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The multi-level analyses were computed using MPLUS version 6.1 (Mplus, 
2010). Consistent with the recommendations of Cohen, Cohen, West, and Aiken (2003) 
and Luke (2004), level 1 predictors were group mean centered and level 2 predictors 
were grand mean centered. Due to the highly positively skewed nature of the SWM 
distributions, traditional ordinary least squares linear regression was deemed 
inappropriate due to the severe violation of normality. Negative binomial regressions 
were used to analyze SWM data. Negative binomial regression is a generalized linear 
model that accounts for a highly positively skewed distribution and is used with count 
data (Agresti, 2007). The negative binomial distribution is unimodal, positively skewed 
over nonnegative integer values, and unlike a Poisson distribution, does not assume 
equivalence of the mean and variance. Negative binomial regression is similar to Poisson 
regression; however, it includes the D parameter in the model which allows the variance 
to be greater than the mean.
4
 Analysis of the D parameter indicated that the SWM data 
had negative binomial, rather than Poisson, distributions.  
Tables 3 and 4 presents the multi-level regression analyses used to examine the 
relation between positive and negative schizotypy and SWM. Positive and negative 
schizotypy were entered at the first step, so the effects of each can be assessed with the 
other partialed out. Table 3 presents the direct effects of positive schizotypy and negative 
schizotypy with SWM performance. As expected, negative, but not positive, schizotypy 
was generally related to SWM outcomes. In particular, negative schizotypy was 
                                                          
4
 Note that a Poisson distribution assumes that the mean and variance are equivalent. However, subject 
heterogeneity often results in a variance that is larger than the mean, which is called overdispersion. 
Overdispersion is measured by the dispersion parameter (D), which summarizes the extent of 
overdispersion relative to a Poisson distribution (Agresti, 2007).  
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significantly associated with increased within and double errors, and slower mean token 
search-preparation time. Contrary to hypotheses, positive schizotypy was associated with 
elevated between errors. 
 Table 4 presents the results from the cross-level interaction analyses, which 
examined whether positive schizotypy and negative schizotypy moderated the association 
between trial type (i.e., 4, 6, or 8 block conditions) and SWM domain performance. There 
were significant relations between the level 1 SWM predictors and criterions. Negative 
schizotypy moderated these relations for within errors, double errors, mean time to first 
response, and mean token search-preparation time. Note that traditional simple slopes 
analyses cannot be performed in MPLUS (P. Silvia, personal communication, May 6, 
2011); therefore, the raw data was graphed in HLM 6 (Raudenbush, Bryk, & Congdon, 
2004) to aid with the interpretation of cross-level interactions. Because raw data were 
used, these results should be interpreted cautiously. The graphs suggested that negative 
schizotypy moderated the association between trial type and SWM performance such that 
high and low negative schizotypy was unrelated to within and double errors on the hard 
trials; however, high negative schizotypy was associated with increased within and 
double errors on the easy trials as well (see Figure 2). In addition, the graphs indicated 
that negative schizotypy moderated the association between trial type and latency such 
that high negative schizotypy performed slower as trial type increased (see Figure 3). 
Positive schizotypy did not moderate any of the relations between the level 1 SWM 
predictors and criterions.  
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Does COMT Moderate the Association of Schizotypy and SWM? 
Consistent with the aforementioned analyses, multi-level modeling and negative 
binomial regressions were used due to the nature of the data. Positive and negative 
schizotypy were entered at the first step as level 2 variables. COMT was entered at the 
second step as an additional level 2 variable. The COMT X positive schizotypy and 
COMT X negative schizotypy interaction terms were entered at the third step to examine 
their effects over-and-above the main effects.  
Table 5 presents the direct effects of positive schizotypy, negative schizotypy, 
COMT, and positive schizotypy X COMT and negative schizotypy X COMT interaction 
terms with SWM performance. Negative schizotypy was significantly associated with 
increased within and double errors. Contrary to hypotheses, positive schizotypy was 
related to increased between errors and COMT was unrelated to any SWM outcomes. 
The positive schizotypy X COMT and negative schizotypy X COMT interaction terms 
were generally unrelated to SWM performance. However, there was a significant relation 
between double errors and the COMT X negative schizotypy interaction. In order to 
decompose this interaction, the slope for negative schizotypy and double errors was 
evaluated at each level of COMT: Met/Met genotype: γ = 15.167 (SE = 5.799), p<.01; 
Val/Met genotype: γ = 1.634 (SE = 1.645), n.s; Val/Val genotype: γ = 2.002 (SE = 
2.169), n.s. This suggests that COMT moderated the relation between negative 
schizotypy and double errors such that the effect is only seen in individuals with Met/Met 
genotype. In other words, negative schizotypy was unrelated to double errors for 
individuals with Val/Val or Val/Met genotypes; however, negative schizotypy had a 
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significant positive association with double errors for individuals with the Met/Met 
genotype. 
Table 6 summarizes the results from the cross-level interaction analyses, which 
examined whether COMT, positive schizotypy, negative schizotypy, and the positive 
schizotypy X COMT, and negative schizotypy X COMT interaction terms moderated the 
association between trial type (i.e., 4, 6, or 8 block conditions) and SWM domain 
performance. There were significant relations between all level 1 SWM predictors and 
criterions. Negative schizotypy moderated these relations for mean time to first response 
and mean token search-preparation time such that high negative schizotypy performed 
slower as trial type increased. Finally, the COMT X negative schizotypy interaction was 
significant. The change in the slope of trial type and double errors across negative 
schizotypy was evaluated at each level of COMT: Met/Met genotype: γ = -13.594 (SE = 
5.917), p<.05; Val/Met genotype: γ = -2.820 (SE = 2.069), n.s; Val/Val genotype: γ = -
0.751 (SE = 2.084), n.s.
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CHAPTER IV 
DISCUSSION 
 
 
The Schizotypy Framework 
 Current theoretical models conceptualize schizophrenia as a neurodevelopmental 
disorder, the vulnerability of which is expressed across a broad continuum of impairment 
called schizotypy. The schizotypy continuum ranges from relative psychological health to 
subclinical deviance to schizophrenia-spectrum personality disorders to full-blown 
schizophrenia. In other words, schizophrenia and schizophrenia-spectrum disorders 
represent the most extreme expressions of illness along the schizotypy continuum. 
Schizotypy is also conceptualized as multidimensional in nature, with positive and 
negative schizotypy being the most consistently replicated dimensions. However, other 
factors have been proposed such as paranoid and disorganized dimensions (e.g., Stefanis 
et al., 2004).  There are many advantages to the schizotypy model. First of all, it allows 
us to examine the etiology of schizophrenia relatively untainted by the illness itself. 
Indeed, factors such as hospitalization, medication, and social stigma undoubtedly 
confound our ability to understand relevant etiological factors. Secondly, it helps identify 
risk and protective factors that may impact the possibility of remaining relatively 
compensated or decompensating into a diagnosable disorder. Finally, the development 
and success of prophylactic interventions is based on the reliable identification of 
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individuals vulnerable for developing spectrum disorders. The multidimensional model of 
schizotypy provides a promising point of entry for developing such treatments.  
Several lines of evidence support the use of psychometric screening inventories as 
promising tools for identifying individuals along the schizoypy continuum. For example, 
scores on psychometric screening inventories are related to and predict a wide range of 
factors relevant to the etiology of schizophrenia including genetic, biobehavioral, 
cognitive, and clinical markers. Moreover, they reliably predict the development of 
schizophrenia-spectrum disorders in longitudinal studies. However, the psychometric 
method has been criticized due to the belief that it identifies false positives. This criticism 
seems to confuse diagnostic-based criterion validation with that of construct validation. 
Criterion validation is often used in prodromal research when the goal is to identify 
individuals who will transition into schizophrenia. This is a useful approach for research 
that focuses on the development and implementation of preventative interventions since 
transition into a spectrum disorder is often used as an index of treatment success. 
Construct validation is appropriate in the case of multidimensional schizotypy (consistent 
with Clairidge or Meehl’s conceptualizations) in which the goal is to test predictions 
about the etiology and expression of schizotypy (across the range of the construct). The 
construct validation approach is equally interested in milder, transient expressions along 
the schizotypy continuum – even beyond those associated with schizotypal personality 
disorder.  This involves testing and making predictions about pathology associated with 
schizophrenia in nondisordered schizotypes. For example, the finding that neurological 
soft signs are associated with negative, but not positive schizotypy (e.g., Kaczorowski et 
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al., 2009), supports the construct validity of multidimensional schizotypy. Furthermore, 
integrating factors from multiple domains (e.g., family history, psychometric screening, 
subclinical symptoms) should increase our identification of schizotypes at especially high 
risk for developing a spectrum disorder. 
The Present study  
The present study aimed to further the validation of the multidimensional 
construct of schizotypy by investigating the relations and interactions between COMT, 
SWM, and psychometrically identified positive and negative schizotypy. This is the first 
study to assess the relationship between COMT and psychometric inventories aimed at 
assessing the broader schizotypy continuum, as opposed to schizotypal personality 
disorder traits (i.e., the Schizotypal Personality Questionnaire) in nonclinical samples. 
Additionally, no published study has utilized the CANTAB SWM task in a sample of 
psychometrically identified schizotypy. Finally, the present study builds upon and 
extends the current literature by assessing multiple dimensions of schizotypy, using 
advanced statistical techniques appropriate for the nature of the data, and overcoming the 
limitations of Smyrnis et al. (2007) by employing a priori hypotheses and appropriate 
statistics to examine the interaction of SWM, COMT, and schizotypy.  
As hypothesized, negative, but not positive, schizotypy was associated with Val 
allele load in an increasing allele-dependent fashion. Additionally, negative, but not 
positive, schizotypy was generally related to SWM outcomes including increased within 
and double errors, as well as a longer mean time to first response and mean token search 
preparation time. However, positive schizotypy was associated with increased between 
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errors. Contrary to hypotheses, COMT was unrelated to SWM performance. The COMT 
X positive schizotypy and COMT X negative schiztoypy interactions were generally 
unrelated to SWM outcomes; however, the COMT X negative schizotypy interaction was 
associated with double errors. These results are generally consistent with the 
schizophrenia literature and support the multidimensional framework of schizotypy. Note 
that the psychometric screening inventories did not inquire about SWM deficits – so the 
results are not simply due to overlapping content in the predictors and criteria. 
Furthermore, the schizotypy dimensional scores identified elevated rates of SWM deficits 
in participants who were drawn from a nonclinically ascertained sample and who were 
functioning well enough to attend college (making for a conservative test of the 
hypotheses—as schizotypes experiencing marked SWM deficits would presumably be 
disadvantaged for gaining college admission).   
Schizotypy and COMT 
 The finding of the hypothesized allele-dependent relation between Val and 
negative, but not positive, schizotypy supports the construct validity of a 
multidimensional model of schizotypy. Moreover, it suggests that COMT contributes to a 
biological differentiation between the two dimensions and grounds negative schizotypy in 
molecular genetics. The present findings are consistent with the notion that negative 
schizotypy serves as a trait-like expression of hypodopaminergic functioning in the 
prefrontal cortex, whereas positive schizotypy may be due, in part, to hyperdopaminergic 
functioning (e.g., Davis et al., 1991). Indeed, positive symptoms have been linked to 
hyperdopaminergic functioning in the striatum (Meyer-Lindenberg et al., 2005). 
 
  
 
37 
 
Although the above statement is undoubtedly an oversimplification of the complex 
processes underlying the development of positive and negative schizotypy, it does 
suggest that the etiology underlying the dimensions may be separate, but related disease 
processes. Conceptualizing and measuring positive and negative schizotypy (and by 
extension schizophrenia) in this manner may help to clarify mixed findings in literature – 
which often treats schizophrenia spectrum disorders as discrete and homogenous entities.  
Stefanis and colleagues (e.g., (Avramopoulos et al., 2002; Smyrnis et al., 2007; 
Stefanis et al., 2004) previously examined this association using the Schizotypy 
Personality Questionnaire, an inventory that assesses schizotypal personality traits based 
on the diagnostic criteria for the disorder. The results supported an association between 
Val allele and schizotypal symptoms, particularly negative and disorganized symptoms. 
The present study broadened these findings to include milder expressions of illness along 
the negative schizotypy continuum. Given that milder expressions of negative schizotypy 
have been associated with the development of schizophrenia spectrum disorders (e.g., 
Kwapil, 1998), it is essential to examine this association across a broad range of 
schizotypy to improve our ability to identify those at risk. In the present study, the linear 
relation between COMT (i.e., number of Val alleles) and negative schizotypy accounted 
for approximately 4% of the variance in negative schizotypy, consistent with Stefanis et 
al. (2004). This small to medium effect size supports the view that the schizotypy 
continuum (including schizotypal personality disorder and schizophrenia) arises from 
multiple genetic and nongenetic factors. Indeed, a number of other genes have been 
implicated in the development of schizophrenia such as DRD1, DTNBP1, MTHFR, and 
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TPH1 (Allen et al., 2008). Future studies should examine how assessing multiple single 
nucleotide polymorphisms or genes within the same functional system may improve our 
understanding of the genetic underpinnings of positive and negative schizotypy. 
The impact of COMT on dopamine metabolism provides a promising mechanism 
for understanding the link between negative symptoms and hypodopaminergic 
functioning in the prefrontal cortex. Negative symptoms reflect a diminution of normal 
functions and scholars dating back to Bleuler (1911/1920) suggested that negative 
symptoms are the fundamental feature of schizophrenia. A small literature has directly 
examined how altering prefrontal dopamine availability differentially impacts 
psychometrically identified positive and negative schizotypy – but no study has examined 
whether this direct relationship is moderated by COMT genotype. In a study examining 
whether controlled dopamine administration impacted language functions, Mohr et al. 
(2005) found increased right hemisphere language contribution was related to increasing 
positive schizotypy scores in a placebo, but not the levodopa, group. In contrast, better 
left hemisphere lexical decision performance was associated with increasing negative 
schizotypy scores in a levodopa group. This suggests that increasing dopamine 
availability contributes to a positive association between negative schizotypy scores and 
improvement in performance on basic language functions. In other words, elevated 
dopamine levels may have a beneficial effect for individuals high on negative schizotypy 
who are presumed to have low baseline levels of dopamine. These findings are in line 
with those of the present study in that they support the notion that dopamine availability 
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differentially impacts positive and negative schizotypy, consistent with a 
multidimensional model of schizotypy.  
Despite its clinical salience, few studies have reported an association between 
COMT and psychometrically identified positive schizotypy. Only Avramopoulos et al. 
(2002) found an association between COMT and the Perceptual Aberration Scale; 
however, the pattern of this finding (i.e., Val homozygotes had the highest scores, 
followed by Met homozygotes, and then Val/Met heterozygotes) is somewhat 
counterintuitive. Note that the authors reported a different pattern using the overall score 
from the Schizotypal Personality Questionnaire in the same study. A questionable 
relation between COMT and positive schizotypy may be due to the notion that positive 
symptoms are presumed to result from a transient neurochemical imbalance due to their 
episodic nature and better response to medication. Moreover, results from brain imaging 
studies suggest an association between positive symptoms and temporal rather than 
prefrontal regions of the brain (e.g., Wible et al., 2009). More research is needed to 
clarify the nature of these relationships – especially given that hyperdopaminergic 
functioning in presumed to contribute to positive symptoms of schizophrenia (e.g., Davis 
et al., 1991).  
Schizotypy and SWM 
 Consistent with predictions, SWM deficits were associated with negative 
schizotypy. These findings support an extant literature documenting the presence of 
working memory deficits in patients with schizophrenia (e.g., Park & Holzman, 1992; 
Forbes et al., 2009; Lee & Park, 2005), as well as schizotypic individuals identified by 
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consanguinity (e.g., Diwadkar et al., 2006), clinical status (e.g., Wood et al., 2003), and 
psychometric screening inventories (e.g., Tallent & Gooding, 1999). In addition, working 
memory has been proposed as an endophenotype for schizophrenia (Gur et al., 2007) – a 
phenotypic expression that is more proximal to the genetic diathesis than the disorder 
itself (Gottesman & Gould, 2003). The presence of working memory deficits across the 
schizotypy continuum supports working memory as an endophenotype and the 
conceptualization of schizophrenia as the most extreme manifestation of illness along the 
schizotypy continuum. 
 A key component of working memory is the ability to maintain mental 
representations active above threshold and under the focus of attention, especially during 
distractions (e.g., Lee & Park, 2005). The present study found an association between 
negative schizotypy and increased within and double errors. In this case, negative 
schizotypy was associated with an impaired ability to hold in memory boxes that did not 
contain a blue token while continuing to search through boxes either within or between 
trials. Interestingly, the cross-level interaction between negative schizotypy and within 
and double errors suggest that individuals high on negative schizotypy made more errors 
even on the easy trials (although this should be interpreted cautiously given that raw data 
was used to interpret the cross-level interaction). Working memory deficits are largely 
controlled by the neural circuitry in the dorsolateral prefrontal cortex, in conjunction with 
the dopaminergic system and posterior parietal cortex (e.g., Goldman-Rakic et al., 2000; 
Wager & Smith, 2003). Many scholars (e.g., Weinberger et al., 2001) suggest that 
working memory deficits contribute to negative symptoms (and thus negative schizotypy) 
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due to impairment in the dorsolateral prefrontal cortex. The results from the present study 
also support an association between negative schizotypy and increased mean time to first 
response and mean token search preparation time. Rather than working memory per se, 
these latency measures likely reflect the processing speed deficits characteristic of 
negative schizotypy (e.g., O’Leary et al., 2000).  
There is a general consensus that positive symptoms are unrelated to working 
memory impairment in schizophrenia (e.g., O’Leary et al., 2000), presumably due to 
positive symptoms being episodic in nature and manageable by medication. However, the 
present study found an unhypothesized relationship between positive schizotypy and 
increased between errors. Rather than indicating working memory deficits per se, this 
association may reflect the distractibility that is characteristic of individuals along the 
positive schizotypy continuum. Several studies (e.g., Green & Walker, 1986; Walker & 
Harvey, 1986) reported that positive symptoms are related to increased vulnerability to 
distraction. Additionally, Diaz et al. (2011) demonstrated that patients with schizophrenia 
fail to show significant differences in brain activation when processing emotional versus 
neutral distractors, suggesting an increased vulnerability to general distraction. Indeed, 
several studies found increased between errors on the CANTAB SWM task in samples 
with unmedicated participants with AD/HD compared to samples with medicated 
participants with AD/HD (e.g., Kempton et al., 1999) or controls (e.g., Goldberg et al., 
2005; Rhodes et al., 2005), supporting the idea that the results from the present study 
reflect distractibility rather than working memory deficits per se. Moreover, marked 
positive symptoms might impair participants’ ability to take part in a working memory 
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task; however, this would likely reflect a more generalized deficit rather than a working 
memory deficit per se. Taken together, the general relation between SWM and negative, 
but positive schizotypy, supports the multidimensional model of schizotypy and suggests 
a differential cognitive pattern between the two dimensions.  
Note that this is the first study to use the CANTAB SWM task in a sample of 
psychometrically identified schizotypy. The results are consistent with those found in the 
patient and relative literature and suggest that the CANTAB SWM task is sensitive 
enough to detect small effect sizes in a nonclinical sample. However, the statistical 
techniques commonly used in the literature (i.e., zero-order correlations, t-tests, unilevel 
linear regression) would have likely masked this relationship. Therefore, the present 
study utilized mixed-modeling and negative binomial regressions to account for the 
nested and skewed nature of the data. To date, this is the only published study to take this 
statistical approach with the CANTAB SWM task within the schizotypy and 
schizophrenia literature. Future studies should consider this approach when analyzing 
similar data – especially when using nonclinical samples in which one would expect 
small to medium effect sizes.  
Schizotypy, COMT, and SWM 
 Contrary to hypotheses, there was no relation between COMT and SWM 
performance. Additionally, COMT genotype generally did not moderate the association 
between SWM performance and negative schizotypy; however, the COMT X negative 
schizotypy interaction was related to double errors. Although Smyrnis et al. (2007) 
reported an allele-dependent relation between negative schizotypy and cognitive 
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performance, the results are largely uninterpretable due to their use of unstandardized 
coefficients and their post-hoc decision to drop latent factors. Thus, this appears to be the 
first published study to appropriately assess this relationship.  
 Due to its role in dopamine metabolism in the prefrontal cortex, a large literature 
has investigated the moderating role of COMT on prefrontally mediated cognitive 
processes, including working memory, in both healthy controls and patients with 
schizophrenia. The literature continues to be inconsistent regarding this relationship. For 
example, several seminal studies suggest that COMT genotype differentially impacts 
prefrontally mediated cognitive performance (e.g., Egan et al., 2001; Goldberg et al., 
2003), meta-analyses yield conflicting results (e.g., Barnett et al., 2007; Barnett et al., 
2008), and more recent work (e.g., Wishart et al., 2011; Wirgenes et al., 2010) supports 
this relation. These inconsistent findings do not suggest that COMT is unrelated to 
prefrontally mediated cognitive processes. Rather, they likely suggest that COMT plays a 
small role in contributing to variation in these relations (e.g., Barnett et al., 2008). 
Moreover, heterogeneity across samples and tasks likely contributes to mixed findings. 
Future meta-analyses should investigate the moderating role of sample and task 
characteristics in studies (e.g., age, sex, symptom presentation, type of task) that assess 
this relationship. 
 The present study found a significant relation between double errors and the 
COMT X negative schizotypy interaction. Contrary to hypotheses, negative schizotypy 
was unrelated to double errors for individuals with Val/Val or Val/Met genotypes, but 
negative schizotypy had a significant positive association with double errors for 
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individuals with the Met/Met genotype. It is difficult to interpret these results because 
Met homozygosity is fairly consistently associated with better, rather than worse, 
prefrontally mediated cognitive performance (e.g., Egan et al., 2001; Mattay et al., 2003; 
Barnett et al., 2010). Moreover, drawing upon Mohr et al. (2005), one might predict 
increased prefrontal dopamine availability (associated with Met/Met genotype) to provide 
a cognitive advantage for negative schizotypy (which is presumably associated with 
prefrontal hypodopaminergic functioning). Rather than suggesting a meaningful 
relationship, this association may reflect a Type I error. More research is needed to 
clarify the nature of this relationship in psychometrically identified positive and negative 
schizotypy to determine whether this result can be replicated.   
Recent studies have assessed multiple genes or single-nucleotide polymorphisms 
within the same functionally related systems. In a sample of healthy children, Barnett et 
al. (2011) found an interaction between MAOA and COMT such that increased prefrontal 
catecholamine availability was related to better working memory in males. Specifically, 
MAOA genotype differentially impacted working memory only in the context of COMT 
Met homozygosity. The results support the idea that COMT is one source of variation 
that contributes to working memory processes. Moreover, understanding how COMT 
interacts with other genes and single-nucleotide polymorphisms will improve our ability 
to understand the genetic basis of prefrontally mediated cognitive processes. However, 
even complex genetic pathways require understanding of the neurobiological pathways 
and environmental contributors to cognitive functioning. 
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Implications  
The relations between COMT and SWM with negative schizotypy support 
schizotypy as an expression of neurodevelopmental vulnerability for schizophrenia. 
Moreover, the results corroborate the notion that neural dysmaturation predates the 
appearance of schizophrenia and can be detected across the schizotypy continuum. The 
general lack of interaction between COMT and negative schizotypy in the prediction of 
SWM highlights the importance of assessing multiple genes or single nucleotide 
polymorphisms in order to better understand the genetic basis of the cognitive processes 
associated with negative schizotypy.  
The differential relation between COMT and SWM and positive and negative 
schizotypy supports the multidimensional construct of schizotypy. This does not mean, 
however, that schizotypy is limited to only two factors. Although the positive and 
negative symptom dimensions are the most widely reported factors of schizotypy and 
schizophrenia, the focus on and identification of these factors admittedly reflects the 
nature of the measures administered. Furthermore, although psychometric screening tools 
providing promising starting points for identifying schizotypy, they undoubtedly lack the 
sensitivity and specificity for assessing schizotypy that structured interviews possess. 
 There are two predominant views regarding the underlying nature of schizotypy. 
Some scholars (e.g., Claridge, 1986) regard schizotypy as being a fully dimensional 
model of personality. Others (e.g., Meehl, 1962) theorize that schizotypy is taxonic in 
nature, representing a pathological process of neurodevelopment. Taxometric methods 
and finite mixture modeling support schizotypy as taxonic in nature
 
(Lenzenweger & 
 
  
 
46 
 
Korfine, 1992; Lenzenweger, McLachlan, & Rubin, 2007). Despite these differing 
conceptualizations, both viewpoints regard schizotypy as a multidimensional model with 
increasing expressions of severity along the continuum. The purpose of the present study 
was not to resolve whether schizotypy is continuous or discontinuous in nature, but rather 
to further validate the multidimensional construct of schizotypy. However, construct 
validation of these dimensions should help clairfy this larger issue.  
 The present study also supports the psychometric methods as a promising tool for 
detecting variation related to COMT, SWM, and schizotypy. The psychometric method is 
a promising point of entry but should be used in combination with other domains relevant 
to multidimensional schizotypy (e.g., genetic, biobehavioral, cognitive, and clinical) to 
better understand the etiology of schizophrenia. This will provide a basis for longitudinal 
study, which will further our understanding of multidimensional schizotypy, and 
contribute to the development of preventative interventions. 
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APPENDIX A: 
TABLES AND FIGURES 
 
 
Table 1 
Descriptive Statistics 
 
 
 
 
 
 
 
  
  N Min Max Mean SD Skew Kurtosis 
Positive Schizotypy  369 -1.56 3.25 -.27 .86 1.20 1.56 
Negative Schizotypy  369 -1.70 4.02 -.03 .95 .76 .68 
Positive Schizotypy (transformed) 369 .00 .76 .33 .15 .30 -.31 
Negative Schizotypy (transformed) 369 .00 .83 .40 .15 -.14 -.38 
COMT 312 0 2 1.09 .732 -.136 -1.121 
Between Errors Total 369 0 93 19.77 15.14 1.12 1.60 
Between Errors - 4 blocks 369 0 11 .53 1.41 3.81 17.75 
Between Errors - 6 blocks 369 0 29 4.82 5.42 1.41 1.90 
Between Errors - 8 blocks 369 0 53 14.41 10.76 .73 .036 
Within Errors Total 369 0 17 .79 1.84 4.41 26.87 
Within Errors - 4 blocks 369 0 9 .08 .63 10.57 129.42 
Within Errors - 6 blocks 369 0 5 .16 .62 4.72 24.77 
Within Errors - 8 blocks 369 0 16 .55 1.51 5.85 47.85 
Double Errors Total 369 0 13 .44 1.23 5.41 39.83 
Double Errors - 4 blocks 369 0 3 .02 .21 10.60 126.17 
Double Errors - 6 blocks 369 0 4 .07 .35 6.89 58.58 
Double Errors - 8 blocks 369 0 13 .35 1.10 6.40 57.45 
Mean Time to First Response – 4 369 .55 4.61 1.28 .60 2.71 9.48 
7
1
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Mean Time to First Response - 6  369 .51 4.16 1.36 .53 1.73 4.27 
Mean Time to First Response - 8  369 .58 6.03 1.52 .64 2.08 7.88 
Mean Time to Last Response - 4   369 8.85 25.18 12.33 2.05 1.64 5.11 
Mean Time to Last Response - 6  369 13.98 33.74 20.47 3.91 .89 .56 
Mean Time to Last Response - 8  369 20.07 77.32 32.44 7.31 1.57 5.25 
Mean Search Preparation Time - 4 369 .49 2.23 .89 .25 1.47 3.19 
Mean Search Preparation Time - 6  369 .48 2.55 .90 .27 1.53 4.72 
Mean Search Preparation Time - 8  369 .47 2.86 .93 .31 1.89 6.25 
Strategy 369 18 47 30.75 5.92 -.32 -.57 
7
2
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Table 2 
Spearman Correlations 
  
 
Positive 
Schizotypy  
(n=369) 
Negative 
Schizotypy  
(n=369) 
COMT
1
 
(n=311) 
Between Errors Total .084 -.009 -.053 
Between Errors - 4 blocks .06 -.009 -.075 
Between Errors - 6 blocks .076 .030 -.013 
Between Errors - 8 blocks .064 -.019 -.058 
Within Errors Total .008 .066 .038 
Within Errors - 4 blocks .066 .137** .059 
Within Errors - 6 blocks -.021 .060 -.006 
Within Errors - 8 blocks .018 .025 .059 
Double Errors Total .013 .063 .059 
Double Errors - 4 blocks .056 .075 .019 
Double Errors - 6 blocks -.03 .086+ .037 
Double Errors - 8 blocks .020 .023 .058 
Mean Time to First Response – 4  -.004 -.071 .073 
Mean Time to First Response - 6  .031 .106* .058 
Mean Time to First Response - 8  .054 .102* .030 
Mean Time to Last Response - 4  .011 .072 .039 
Mean Time to Last Response - 6  .041 .102* .033 
Mean Time to Last Response - 8  .057 .076 .022 
Mean Search Preparation Time - 4 -.005 .060 .038 
Mean Search Preparation Time - 6  .038 .119* .070 
Mean Search Preparation Time - 8  .055 .124* .063 
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Strategy .123* .025 .016 
Positive Schizotypy  .22*** -.022 
Negative Schizotypy   .195*** 
***p<.001 **p<.01 *p ≤ .05 +p < .10 
1
Note the correlations between positive and negative schizotypy and COMT contained 
312 participants. 
 
75 
 
Table 3 
Direct Effects of Positive and Negative Schizotypy with SWM Performance  
(N = 369)          
 
**p<.01 *p ≤ .05 +p<.10 
Note. Values are multilevel modeling coefficients (and standard error). 
 Level 2 Predictors 
 
SWM Level 1 
Criterion 
Step 1:  
Positive Schizotypy 
 
Step 1:  
Negative Schizotypy  
 
   
Between Errors 0.892(SE=0.370)* -0.356(SE=0.376) 
Within Errors    0.400(SE=1.119) 2.578(SE=1.024)* 
Double Errors 0.852(SE=1.188) 2.871(SE=1.069)
 
** 
Time to First 
Response 
0.091(SE=0.176) 0.380(SE=0.202)
 
+ 
Time to Last 
Response 
1.230(SE=1.221) 2.189(SE=1.372) 
Preparation time  0.026(SE=0.077) 0.197(SE=0.092)*
 
Strategy 1.021(SE=2.383) -0.134(SE=0.523) 
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Table 4 
Cross Level Interaction of Positive and Negative Schizotypy with SWM 
Performance (N = 369) 
 
***p<.01 **p<.01 *p≤ .05  
Note. Values are multilevel modeling coefficients (and standard error)
  Level 2 Predictors 
SWM  
Level 1  
Criterion 
Relation of Level 1 
predictor and criterion 
 
Step 1: 
Positive  
Schizotypy 
  
  
Step 1: 
Negative  
Schizotypy 
  
 
    
Between Errors 1.649(SE=0.042)*** -0.404(SE=0.298) 0.290(SE=0.294) 
Within Errors    1.411(SE=0.171)*** -0.256(SE=1.322) -2.232(SE=1.001)* 
Double Errors 1.675(SE=0.232)*** -0.734(SE=1.417) -2.762(SE=1.206)* 
Time to First 
Response 
0.117(SE=0.015)*** 
0.118(SE=0.080) 0.221(SE=0.102)* 
Time to Last 
Response 
10.052(SE=.166)*** 0.898(SE=0.954) 1.105(SE=1.067) 
Preparation time    0.018(SE = 0.007)** 0.042(SE=0.038) 0.102(SE=0.048)* 
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Table 5 
Direct Effects of Positive and Negative Schizotypy with SWM Performance (N = 311) 
 Level 2 Predictors 
 
SWM Level 1 
Criterion 
Step 1:  
Positive  
Schizotypy 
 
Step 1:  
Negative  
Schizotypy  
 
Step 2: 
COMT 
Step3: 
COMT X 
Positive 
Schizotypy 
 
Step 3: 
COMT X 
Negative 
Schizotypy 
 
Between 
Errors 
1.062(SE=0.400)** -0.418(SE=0.388) 
 
-0.051(SE=0.080) 
 
0.279 (SE=0.586) 
 
-0.031 (SE=0.565) 
 
Within Errors  
0.618(SE=1.156) 
 
2.127(SE=1.072)* -0.007 (SE=0.227) 0.560 (SE=1.396) -1.469 (SE=1.576) 
 
Double Errors 
1.304 (SE=1.276) 
 
2.612 (SE=1.298)* 
 
0.110 (SE=0.268) 
 
0.603 (SE=1.476) 
 
-3.836 (SE=1.934)* 
 
Time to First 
Response 
0.058 (SE=0.191) 
 
0.292(SE=0.213) 
 
0.024(SE=0.043) 
 
-0.283 (SE=0.280) 
 
0.295(SE=0.320) 
 
Time to Last 
Response 
0.778(SE=1.351) 2.203(SE=1.537) 0.238 (SE=0.325) -1.822 (SE=1.868) -0.209(SE=2.439) 
 
Preparation  
-0.025(0.084) 
 
0.170(SE=0.099)+ 
 
0.018(SE=0.020) 
 
-0.118(SE=0.117) 
 
0.051(SE=0.155) 
 
Strategy 
1.024(SE=2.934) 
 
-0.269(SE=0.920) 
 
0.187(SE=0.685) 
 
-0.065(SE=0.096) 
 
-0.045(SE=0.102) 
 
 
7
7
 
**p < .01 *p ≤ .05 
+
p<.10 
Note. Values are multilevel modeling coefficients (and standard error)   
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Table 6 
Cross Level Interaction of Positive and Negative Schizotypy with SWM Performance (N = 311) 
  Level 2 Predictors 
SWM  
Level 1  
Criterion 
Relation of 
Level 1 
predictor and 
criterion 
 
Step 1: 
Positive  
Schizotypy 
 
Step 1: 
Negative  
Schizotypy 
 
Step 2: 
COMT 
 
Step 3: 
COMT X 
Positive 
Schizotypy 
 
Step 3: 
COMT X 
Negative 
Schizotypy 
 
Between Errors  1.646 
(SE=0.045)*** 
-0.446 
(SE=0.330) 
0.429 
(SE=0.313) 
0.006 
(SE=0.063) 
-0.630 
(SE=0.453) 
0.016 
(SE=0.437) 
 
Within Errors 
 
1.418 
(SE=0.186)*** 
-0.818 
(SE=1.375) 
-1.694 
(SE=1.083) 
0.131 
(SE=0.253) 
1.253 
(SE=1.619) 
0.624 
(SE=1.459) 
 
Double Errors  
1.733 
(SE=0.270)*** 
-1.380 
(SE=1.522) 
-2.302 
(SE=1.485) 
0.071 
(SE=0.306) 
-1.502 
(SE=1.838) 
4.221 
(SE=2.010)* 
 
Time to  
First Response 
0.120 
(SE=0.017)*** 
0.112 
(SE=0.089) 
0.260 
(SE=0.117)* 
0.020 
(SE=0.026) 
0.108 
(SE=0.139) 
-0.060 
(SE=0.189) 
 
Time to  
Last Response 
10.130 
(SE=0.183)*** 
0.855 
(SE=1.015) 
1.297 
(SE=1.174) 
0.200 
(SE=0.277) 
-1.067 
(SE=1.432) 
-0.496 
(SE=1.875) 
 
Prep time  0.020 
(SE=0.008)** 
0.017 
(SE=0.039) 
0.147 
(SE=0.052)** 
0.008 
(SE=0.012) 
0.012 
(SE=0.055 
-0.072 
(SE=0.077) 
***p ≤ .001 **p < .01 *p ≤ .05  
 
Note. Values are multilevel modeling coefficients (and standard error) 
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Figure 1. Mean Positive and Negative Schizotypy Scores Associated with COMT 
Genotype. 
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Figure 2. The Cross Level Interaction of Negative Schizotypy with Trial Type and Within 
Errors. 
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Figure 3. The Cross Level Interaction of Negative Schizotypy with Trial Type and Mean 
Time to First Response. 
 
 
